Want to join the conversation?
Related to the acquisition of Par Pharmaceutical on Sept. 25, 2015, $ENDP implemented cost-rationalization and integration initiatives to capture operating synergies and generate cost savings across the company. The cost reduction initiatives included a reduction in headcount of approx. 6% of the former Par and Qualitest workforces.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.